Supplementary Table I. Antibodies used for immunophenotyping

Antibody	Fluorochrome	Clone	Catalog #	Company
CD3ε	APC-Cy7 or PE-Cy5	145-2C11	557596/553065	BD Biosciences
CD4	APC or AF 700	RM4-5	553051/561025	BD Biosciences
CD8	PE-CF594 or PE-Cy5	53-6.7	562283/561094	BD Biosciences
CD25	PE-Cy7	PC61	552880	BD Biosciences
CD154/CD40L	APC	MR1	17-1541-82	eBioscience
CD279/PD-1	FITC	J43	11-9985-85	eBioscience
CD69	PE-CF594	H1.2F3	562455	BD Biosciences
CD152/CTLA-4	PE	UC10-4F10-11	561718	BD Biosciences
CD11b	PE-CF594	M1/70	562287	BD Biosciences
Ly6G	APC	1A8	560599	BD Biosciecnces
F4/80	APC-efluor 780	BM8	47-4801-82	eBioscience
iNOS	PE	CXNFT	12-5920-82	eBioscience
IL4	PE-Cy7	11B11	560699	BD Biosciences
IFNγ	V450	XMG1.2	560661	BD Biosciences
CD49b/DX5	APC	DX5	560628	BD Biosciences
NK1.1	AF 700	PK136	560515	BD Biosciences
TCR-β	PerCP-Cy 5.5	H57-597	560657	BD Biosciences
CD44	APC-Cy7	IM7	560568	BD Biosciences
CD11c	AF488	N418	53-0114-82	eBioscience
DEC205	PerCP-eFluor 710	205yekta	46-2051-82	eBioscience
IL-10	AF700	JES5-16E3	56-7101-82	eBioscience
CD16/CD32	N/A	2.4G2	553142	BD Biosciences
CD1d Tetramer loaded with α-Galcer	PE	N/A	N/A	NIH

Supplementary Table II. Primers used for individual RT-PCRs

Gene Name	Gene Symbol	Assay ID	Company
β-actin	*Actb*	Mm00607939_s1	Invitrogen/Applied Biosystems
Chemokine (C-C motif) ligand 1	*Ccl1*	Mm00441236_m1	Invitrogen/Applied Biosystems
Chemokine (C-C motif) ligand 12	*Ccl12*	Mm01617100_m1	Invitrogen/Applied Biosystems
Chemokine (C-C motif) ligand 2	*Ccl2*	Mm00441242_m1	Invitrogen/Applied Biosystems
Fatty acid binding protein 4	*Fabp4*	Mm00445878_m1	Invitrogen/Applied Biosystems
Long-chain fatty acid transport protein 4	*Fatp4*	Mm01327405_m1	Invitrogen/Applied Biosystems
Tumor necrosis factor α	*Tnf*	Mm00443258_m1	Invitrogen/Applied Biosystems



Supplementary Figure 1. Fetal, placental, and neonatal weights. (**A&B**) Fetuses and placentae from dams i.v. injected with 2μg of α-GalCer or DMSO were weighed 6 h post-injection. Data are pooled from 6-8 litters (n=38 for DMSO and n=58 for α-GalCer). (**C**) Neonates delivered by dams i.v. injected with 2μg of α-GalCer or DMSO were weighed at 1 week postpartum. Data are from independent neonates (n=57 for DMSO and n=46 for α-GalCer).



Supplementary Figure 2. CD1d-restricted iNKT cells in the liver, myometrium, spleen, and lymph nodes. Number of CD1d-restricted iNKT cells in the liver (**A**), myometrium (**B**), Spleen (**C**), and uterine lymph nodes (**D**) from mice injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + rosiglitazone. Data are representative of individual dams, n=6-8 each.



Supplementary Figure 3. IFNγ+ CD1d-restricted iNKT cells in decidual tissues. Number of IFNγ+ CD1d-restricted iNKT cells in decidual tissues from mice injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + rosiglitazone. Data are from individual dams, n=6-8 each.



Supplementary Figure 4. Activated CD4+ and CD8+ T cells in decidual tissues. (**A**) Proportion of CD25+CD4+ T cells and PD1+CD4+ T cells in decidual tissues from mice injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + rosiglitazone. (**B**) Proportion of CD25+CD8+ T cells and CD69+CD8+ T cells in decidual tissues from mice injected with DMSO, α-GalCer, rosiglitazone, or α-GalCer + rosiglitazone. Data are from individual dams, n=6-8 each.



Supplementary Figure 5. Number of IFNγ+ neutrophils in myometrial tissues from mice injected with DMSO, α-GalCer, rosiglitazone (Rosi), or α-GalCer + rosiglitazone. Data are from individual dams, n=6-8 each.



Supplementary Figure 6. Viability of decidual cells after treatment with rosiglitazone. Cell viability of decidual leukocytes (CD45+ cells) was determined by flow cytometry after 6 hrs of incubation with DMSO (rosiglitazone vehicle), rosiglitazone, or without either treatment (control).